SCHEMBL6884841

SCHEMBL6884841

CC(C)(C)c1cc(C=C2SC(=S)N(C(CCCC(=O)O)CC(=O)O)C2=O)ccc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
GAA P10253 2/20 0.46
PSMD14 O00487 1/20 0.46
NSD2 O96028 1/20 0.46
ALPL P05186 1/20 0.46
MMP2 P08253 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
GFER P55789 1/20 0.46
MAPT P10636 4/20 0.45
MAPK1 P28482 3/20 0.45
RECQL P46063 2/20 0.45
FABP4 P15090 1/20 0.45
ALDH1A1 P00352 1/20 0.45
OPRK1 P41145 1/20 0.45
BLM P54132 1/20 0.45
THRB P10828 1/20 0.45
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6883757 0.81 MAPT (0.48) POLBMEN1KMT2AMAPTALDH1A1
SCHEMBL6888296 0.79 CTNNB1 (0.52) POLBMEN1KMT2AGAAPSMD14
SCHEMBL6884833 0.79 MEN1 (0.51) POLBMEN1KMT2AGAAPSMD14
SCHEMBL6884835 0.79 MEN1 (0.51) POLBMEN1KMT2AGAAPSMD14
SCHEMBL6884300 0.77 MAPT (0.60) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL6884984 0.77 MEN1 (0.51) MEN1KMT2AMAPTMAPK1ALDH1A1
SCHEMBL6881179 0.74 BCL2 (0.52) POLBMEN1KMT2AMAPTMAPK1
SCHEMBL6881182 0.74 BCL2 (0.52) POLBMEN1KMT2AMAPTMAPK1
SCHEMBL6879808 0.74 MAPT (0.52) POLBMEN1KMT2AGAAMAPT
SCHEMBL6886501 0.74 MAPT (0.52) POLBMEN1KMT2ANSD2ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673816-B1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Esswein, Angelika (DE) 2004-01-06 US disclosed
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD 2003-02-13 US disclosed
EP-1117655-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS Esswein, Angelika (DE) 2001-07-25 EP disclosed
WO-2000018747-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders NR1H4, NR1D1, NR1I2 POLB 2514/4885MEN1 838/4885KMT2A 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.